Table 2 Choice of study drugs and suggested dosing
OST | Minimum daily dose | Suggested regimen | Acceptable dosing | Dose adjustment |
|---|---|---|---|---|
First choice for MSSA and MRSA: trimethoprim-sulfamethoxazole | 320/1600 mg | 160/800 mg twice a day | Severe renal impairment | |
Alternative for MSSA: clindamycin | 1800 mg | 600 mg three times a day | No | |
Alternative for MRSA: linezolid | 1200 mg | 600 mg twice a day | No | |
IST | ||||
First choice for MSSA: flucloxacillin | 6 g (in at least four doses a day, or continuous infusion) | 2 g four times a day | 4 g three times a day | Severe renal impairment |
First choice MSSA in Spain: cloxacillin | 6 g (in at least four doses a day, or continuous infusion) | 2 g four times a day | 2 g six times a day | No |
Alternative for MSSA: cefazolin | 1 g three times a day | 2 g three times a day | 3 g four times a day | Renal impairment |
Alternative for MSSA and first choice for MRSA: vancomycin | as determined by therapeutic drug monitoring | 1 g twice a day | 20 mg/kg three times a day; loading dose and continuous infusion are accepted | TDM (suggested level: 10 to 20 μg/ml) |
Alternative for MRSA: daptomycin | 6 mg/kg once per day | 6-10 mg/kg once per day | Renal impairment |